<font color="blue">Experimental_1</font> <font color="blue">hyaline_2</font> <font color="blue">membrane_2</font> <font color="blue">disease_2</font> <font color="blue">in_2</font> <font color="blue">the_3</font> <font color="blue">premature_5</font> <font color="blue">monkey_5</font> <font color="blue">:_5</font> effects of antenatal dexamethasone . 
<br>
<br> A blind , randomized trial of antenatal glucocorticoid treatment was conducted using <font color="blue">the_1</font> <font color="blue">premature_3</font> <font color="blue">monkey_3</font> <font color="blue">(_3</font> <font color="blue">Macaca_3</font> <font color="blue">nemestrina_3</font> <font color="blue">)_3</font> <font color="blue">model_2</font> <font color="blue">of_2</font> <font color="blue">hyaline_2</font> <font color="blue">membrane_2</font> <font color="blue">disease_2</font> <font color="blue">(_2</font> <font color="blue">HMD_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> <font color="blue">Twelve_3</font> <font color="blue">dams_3</font> <font color="blue">received_1</font> <font color="blue">dexamethasone_1</font> ( 2 mg / dose ) 72 , 48 , and 24 h before abdominal delivery at 135 + /- 1 days of gestation . <font color="blue">Twelve_2</font> <font color="blue">control_2</font> <font color="blue">animals_2</font> <font color="blue">received_1</font> <font color="blue">saline_1</font> <font color="blue">._1</font> <font color="blue">Infants_2</font> <font color="blue">of_2</font> <font color="blue">dexamethasone_2</font> <font color="blue">-_2</font> <font color="blue">treated_2</font> <font color="blue">dams_2</font> had significantly lower incidence and severity of HMD than did infants of control animals ( 50 versus 92% , p less than 0.05 ) . Improvement with treatment was markedly greater for <font color="blue">males_1</font> <font color="blue">than_1</font> <font color="blue">for_1</font> <font color="blue">females_1</font> <font color="blue">._1</font> Differences in volume - pressure behavior of the excised lungs included greater distensibility in the infants from <font color="blue">dexamethasone_1</font> <font color="blue">-_1</font> <font color="blue">treated_1</font> <font color="blue">dams_1</font> ( 20.6 + /- 7.1 ml / g dry lung versus 14.7 + /- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment . Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone - treated dams was indicated by increases in total lung phospholipid ( 84.5 + /- 8.1 mg / g dry lung versus 75.1 + /- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 + /- 3.33 mg / g dry lung versus 3.01 + /- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 + /- 1.84 mg / g dry lung versus 1.06 + /- 1.05 , p less than 0.05 ) . Incorporation of 14C - palmitate into lung lipid was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the DPC fraction with treatment . Antenatal dexamethasone treatment was successful in reducing the incidence and severity of experimental HMD in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .